Basecamp Research Secures $140 Million Series C Funding for AI-Designed Therapeutics
Basecamp Research, an AI-based drug developer, has successfully closed a $140 million Series C funding round. This significant investment, reportedly valuing the company at $800 million, saw participation from prominent investors including Anthropic and Nvidia. The capital is earmarked to accelerate the development of its AI-designed therapeutics, with a particular focus on advancing cell therapies. The primary announcement originated from Basecamp Research itself, disseminated via a PR Newswire press release, and was subsequently widely reported across numerous media outlets. While the funding amount and key investors are consistently reported, Endpoints News additionally noted the unveiling of a six-program pipeline as part of this announcement. Unite.AI also highlighted the company's intention to train new EDEN models with the raised capital. The company's stated goal is to advance these AI-driven drug candidates towards clinical stages.
16 articles from 16 outlets covered this story. No difference in framing or figures was found between them. The underlying claim is sourced from a press release.
What do all outlets agree on?
16 outlets covered “Basecamp Research Secures $140 Million Series C Funding for AI-Designed Therapeutics”. All of them report the following:
- Basecamp Research raised $140 million
- The funding is a Series C round
- The purpose is to advance AI-designed therapeutics
- Anthropic and Nvidia are among the investors
- The company is an AI-based drug developer
Did outlets disagree about this?
No. All 16 outlets covering “Basecamp Research Secures $140 Million Series C Funding for AI-Designed Therapeutics” reported it the same way — no difference in framing or figures was found between them.
Which outlets covered this?
All 16 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.